STOCK TITAN

Silence Therapeutics Plc American Depository Share - $SLN STOCK NEWS

Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: $SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silence Therapeutics Plc American Depository Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silence Therapeutics Plc American Depository Share's position in the market.

Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) reported strong execution across its mRNAi GOLD™ platform, including positive data from the multiple dose study for zerlasiran in patients with high Lp(a) and stable ASCVD, and progress in the SLN124 phase 1/2 study in polycythemia vera. The company also reviewed recent business highlights and financial results for the third quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
-
Rhea-AI Summary
Silence Therapeutics plc (Nasdaq: SLN) announced that Craig Tooman, President and CEO, will present a corporate update at the Jefferies London Healthcare Conference on November 15th. The webcast can be accessed via the Investors section of the Silence website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
conferences
-
Rhea-AI Summary
Silence Therapeutics announces positive results from the multiple dose component of the APOLLO phase 1 study of zerlasiran. Zerlasiran demonstrated significant reductions in lipoprotein(a) levels of up to 99% and remained around 90% lower than baseline at the end of the treatment period. The drug also showed a dose-dependent reduction in LDL cholesterol and apolipoprotein B. Zerlasiran was well tolerated with no safety concerns identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.25%
Tags
Rhea-AI Summary
Silence Therapeutics plc to participate in fireside chat at Chardan's Genetic Medicines Conference on October 3rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
-
Rhea-AI Summary
Silence Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
conferences
-
Rhea-AI Summary
Silence Therapeutics plc, Nasdaq: SLN, reported its financial results for Q2 2023, with a net loss after tax of £10.4 million. The company achieved several milestones, including completing dosing in the APOLLO phase 1 study and achieving enrollment in the ALPACAR-360 phase 2 study. Silence also received milestone payments of $10.0 million from AstraZeneca and $4.0 million from Hansoh. Revenue for Q2 2023 was £9.1 million, compared to £3.6 million in Q2 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.56%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
none
Silence Therapeutics Plc American Depository Share

Nasdaq:SLN

SLN Rankings

SLN Stock Data

989.66M
72.78M
16.99%
44.6%
0.35%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
London

About SLN

silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com